NCT05922878ClinicalTrials.gov
Study of ALTO-300 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
باختصار
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
المرحلة 2مطلوب 325 مشاركاً75 موقعاًدولة واحدة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT05922878فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل 3 أسابيع
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 325 participants (target), run at 75 sites.
How this score is built
- Enrolment24/40
321 participants (target)
- Site count19/25
45 sites
- Country count0/15
Single country
- Planned duration8/10
Planned over about 42 months
- Sponsor scale2/10
Alto Neuroscience has led 5 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
الحالات
- Major Depressive Disorder
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 18 Years – 70 Years |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 2 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 325 مشاركاً |
الجهة الراعية والمتعاونون
- Alto Neuroscience الجهة الراعية
الأذرع والتدخلات
- ALTO-300EXPERIMENTAL
Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).
- PlaceboPLACEBO_COMPARATOR
Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.
التدخلات
- دواء ALTO-300
ALTO-300 capsule QD
- دواء Placebo
Placebo capsule QD
مقاييس النتائج
مقياس النتيجة الأولي
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
الإطار الزمني Change over time for up to week 6
مقياس النتيجة الثانوي
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
الإطار الزمني Change over time for up to week 6
مقياس النتيجة الثانوي
To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
الإطار الزمني Change over time for up to week 6
مقياس النتيجة الثانوي
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.
Incidence, severity, and relatedness of Adverse Events
الإطار الزمني Assessed from Day 1 to Week 14
مقياس النتيجة الثانوي
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.
Assessment of Heart Rate
الإطار الزمني Assessed from Day 1 to Week 14
مقياس النتيجة الثانوي
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.
Assessment of Weight Change
الإطار الزمني Assessed from Day 1 to Week 14
مقياس النتيجة الثانوي
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.
Assessment of Blood Pressure
الإطار الزمني Assessed from Day 1 to Week 14
مقياس النتيجة الثانوي
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).
The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.
الإطار الزمني Assessed from Day 1 to Week 15
التواريخ
| تاريخ البدء | 8 يونيو 2023 (فعلي) |
|---|---|
| الإتمام الأولي | 1 ديسمبر 2026 (تقديري) |
| الإتمام | 1 ديسمبر 2026 (تقديري) |
| أول نشر | 28 يونيو 2023 (فعلي) |
| آخر تحديث | 26 أكتوبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | أكتوبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
30 موقعاً قيد التجنيد
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Site 114 | Albuquerque | New Mexico | قيد التجنيد |
| Site 216 | Allentown | Pennsylvania | أُنهي |
| Site 316 | Austin | Texas | قيد التجنيد |
| Site 218 | Bellflower | California | قيد التجنيد |
| Site 317 | Blackfoot | Idaho | مسحوب |
| Site 236 | Boise | Idaho | قيد التجنيد |
| Site 119 | Boise | Idaho | نشط، دون تجنيد |
| Site 318 | Carlsbad | California | نشط، دون تجنيد |
| Site 310 | Chicago | Illinois | نشط، دون تجنيد |
| Site 202 | Cincinnati | Ohio | قيد التجنيد |
| Site 159 | Clermont | Florida | أُنهي |
| Site 207 | Clinton | Utah | نشط، دون تجنيد |
| Site 203 | Colorado Springs | Colorado | نشط، دون تجنيد |
| Site 239 | Conroe | Texas | قيد التجنيد |
| Site 229 | Creve Couer | Missouri | مسحوب |
| Site 102 | Dallas | Texas | نشط، دون تجنيد |
| Site 343 | Denver | Colorado | قيد التجنيد |
| Site 349 | Evergreen | Colorado | نشط، دون تجنيد |
| Site 345 | Evergreen | Colorado | نشط، دون تجنيد |
| Site 277 | Fairfax | Virginia | قيد التجنيد |
| Site 238 | Fayetteville | Georgia | قيد التجنيد |
| Site 148 | Fort Worth | Texas | مسحوب |
| Site 347 | Fort Worth | Texas | أُنهي |
| Site 217 | Glendale | California | نشط، دون تجنيد |
| Site 279 | Hattiesburg | Mississippi | مسحوب |
| Site 199 | Hickory | North Carolina | نشط، دون تجنيد |
| Site 320 | Houston | Texas | قيد التجنيد |
| Site 275 | Houston | Texas | قيد التجنيد |
| Site 215 | Jackson | Mississippi | نشط، دون تجنيد |
| Site 335 | Lafayette | California | قيد التجنيد |
| Site 335 | Lafayette | California | قيد التجنيد |
| Site 344 | Las Vegas | Nevada | قيد التجنيد |
| Site 209 | Los Angeles | California | نشط، دون تجنيد |
| Site 240 | Mankato | Minnesota | قيد التجنيد |
| Site 201 | Marrero | Louisiana | أُنهي |
| Site 219 | Mather | California | قيد التجنيد |
| Site 350 | Media | Pennsylvania | مسحوب |
| Site 225 | Miami Gardens | Florida | نشط، دون تجنيد |
| Site 190 | Miami Lakes | Florida | نشط، دون تجنيد |
| Site 265 | Minneapolis | Minnesota | قيد التجنيد |
| Site 194 | Mission Viejo | California | أُنهي |
| Site 206 | Missouri City | Texas | مسحوب |
| Site 198 | Monroe | Louisiana | أُنهي |
| Site 267 | Moorpark | California | قيد التجنيد |
| Site 352 | Moosic | Pennsylvania | نشط، دون تجنيد |
| Site 283 | New York | New York | قيد التجنيد |
| Site 319 | New York | New York | نشط، دون تجنيد |
| Site 214 | Norwalk | Connecticut | مسحوب |
| Site 161 | Okeechobee | Florida | نشط، دون تجنيد |
| Site 195 | Oklahoma City | Oklahoma | أُنهي |
يُدرَج 25 موقعاً إضافياً في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 26 أكتوبر 2026
تغيّر هدف التجنيد
Enrollment target revised up from 321 to 325
321325
- 26 أكتوبر 2026
أُضيف موقع
30 sites added (75 total)
4575